Recent Updates
Recently added Catalysts

JNJ-26489112

Phase 2

Photosensitive Epilepsy | Small molecule | Neurology |Johnson & Johnson|Last Updated: Apr 5, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment12

FDA Designations

No designations recorded

Clinical trial landscape

JNJ-26489112 · 1 trial · 1 indication

Phase 2 1
NCT00579384A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive EpilepsyPhotosensitive Epilepsy
COMPLETED12 Analytics
PHASE2COMPLETED
A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy
Photosensitive Epilepsy
NCT0057938412
Unlock trial analytics

Study Endpoints

Primary Endpoints

The photosensitivity range in each eye condition (during closure, closed, open) based upon the photoparoxysmal electroencepholgram (EEG) response to intermittent photic stimulation (IPS).
Hours 1 to 8 (Day 2) and 25 to 33 postdose (Day 3) with optional assessments at 48, 52, and 56 hours postdose

Secondary Endpoints

The safety, tolerability, pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of JNJ-26489112.
Day 1 to Day 3 and an optional Day 4
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingSINGLE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
001EXPERIMENTAL -

Interventions

NameTypeDescription
JNJ-26489112DRUGSingle oral dose of JNJ-26489112 up to 3000 mg on Day 2.
PlaceboDRUGSingle dose of placebo on Day 1, and a second single dose of placebo on Day 3.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Males or postmenopausal/surgically sterile females. Post-menopausal is defined as no menses for the 18 months prior to study start. If menses have ceased within 36 months of the start of this study, then plasma follicle stimulating hormone must be elevated to within a post-men...

Unlock Eligibility Criteria

Frequently asked questions about JNJ-26489112

What is JNJ-26489112 used for?

JNJ-26489112 is an investigational small molecule being developed for the treatment of photosensitive epilepsy, a condition in which seizures are triggered by flashing or patterned light. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.

Who makes JNJ-26489112?

JNJ-26489112 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is an investigational small molecule intended for the treatment of photosensitive epilepsy.

What phase is JNJ-26489112 in?

JNJ-26489112 is in Phase 2 clinical development. It is an investigational drug for photosensitive epilepsy and has not been approved by the FDA or any other regulatory agency. One Phase 2 clinical trial has been completed, and no trials are currently active.

What clinical trials is JNJ-26489112 in?

JNJ-26489112 has been studied in one completed Phase 2 clinical trial, identified as NCT00579384. This trial evaluated the effects of JNJ-26489112 on the photic-induced paroxysmal electroencephalogram (EEG) response in patients with photosensitive epilepsy. The trial enrolled 12 participants.

How does JNJ-26489112 work?

JNJ-26489112 is a small molecule being studied for its ability to suppress the abnormal brain activity that causes seizures in people with photosensitive epilepsy. The specific molecular target of JNJ-26489112 has not been disclosed in available information.